[["metastatic thyroid cancers that are refractory to radioiodine", "are associated with", "a poor prognosis"], ["selective MAPK pathway antagonists", "increase", "the expression of the sodium-iodide symporter and uptake of iodine in mouse models of thyroid cancer"], ["the effects of selective MAPK pathway antagonists", "are not known in", "humans"], ["the study", "aimed to determine", "whether selumetinib could reverse refractoriness to radioiodine in patients with metastatic thyroid cancer"], ["selumetinib", "is a", "MEK 1 and MEK2 inhibitor"], ["dosimetry with iodine-124 PET", "was performed before and after", "treatment with selumetinib"], ["therapeutic radioiodine", "was administered if", "a dose of iodine-131 of 2000 cGy or more could be delivered to the metastatic lesions"], ["of 24 patients screened", "20 could be evaluated", "in the study"], ["the median age of evaluated patients", "was", "61 years"], ["11 patients", "were", "men"], ["9 patients", "had", "tumors with BRAF mutations"], ["5 patients", "had", "tumors with NRAS mutations"], ["selumetinib", "increased", "the uptake of iodine-124 in 12 of the 20 patients"], ["4 of 9 patients with BRAF mutations", "increased", "iodine-124 uptake"], ["5 of 5 patients with NRAS mutations", "increased", "iodine-124 uptake"], ["8 of 12 patients", "reached", "the dosimetry threshold for radioiodine therapy"], ["all 5 patients with NRAS mutations", "reached", "the dosimetry threshold for radioiodine therapy"], ["of the 8 patients treated with radioiodine", "5 had", "confirmed partial responses"], ["of the 8 patients treated with radioiodine", "3 had", "stable disease"], ["all patients", "had", "decreases in serum thyroglobulin levels"], ["the mean reduction in serum thyroglobulin levels", "was", "89%"], ["no toxic effects of grade 3 or higher", "were observed", "attributable to selumetinib"], ["one patient", "received", "a diagnosis of myelodysplastic syndrome more than 51 weeks after radioiodine treatment"], ["the diagnosis of myelodysplastic syndrome", "progressed to", "acute leukemia"], ["selumetinib", "produces", "clinically meaningful increases in iodine uptake and retention in a subgroup of patients with thyroid cancer"], ["the effectiveness of selumetinib", "may be greater in", "patients with RAS-mutant disease"]]